Navigation Links
Idenix Pharmaceuticals Reports Third Quarter and Nine Month Financial Results
Date:11/6/2007

CAMBRIDGE, Mass., Nov. 6 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral and other infectious diseases, today reported unaudited financial results for the third quarter and nine months ended September 30, 2007. At September 30, 2007, Idenix's cash, cash equivalents and marketable securities totaled approximately $136.5 million.

For the third quarter ended September 30, 2007, Idenix reported total revenues of $10.9 million, compared with total revenues of $19.6 million in the third quarter of 2006. Total revenues for the third quarter of 2007 consist of reimbursement by Novartis Pharma AG of expenses incurred by Idenix in connection with the development of Tyzeka(R)/Sebivo(R) (telbivudine), valtorcitabine and valopicitabine, Idenix's product and product candidates for the treatment of hepatitis B virus (HBV) and hepatitis C virus (HCV), respectively, and the amortization of the up-front fees received by Idenix in connection with Novartis' license of telbivudine, valtorcitabine and valopicitabine and product sales of Tyzeka/Sebivo. Idenix reported a net loss of $30.5 million, or a loss of $0.54 per basic and diluted share for the third quarter ended September 30, 2007, compared to a net loss of $19.7 million, or a loss of $0.35 per basic and diluted share for the third quarter ended September 30, 2006. Included in the net loss for the third quarter ended September 30, 2007 was a $6.4 million restructuring charge primarily related to severance costs and impairment of certain fixed assets related to the transition of commercialization, development and manufacturing activities for telb
'/>"/>

SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
2. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
3. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
4. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... DMG Productions announces the upcoming airing ... broadcast on Wednesday, September 24, 2014 at 7:30 ... episode, Innovations will go behind the scenes to ... each client the opportunity to achieve the highest ... principles of Care, Compassion, and Commitment. , Audiences ...
(Date:9/17/2014)... 2014 Kristen Yarker, MSc, RD recently announced ... children 9 months to 2 years old who are seeking ... picky eaters from developing by encouraging healthy eating habits from ... to 2 years): How to Transition From Baby Food to ... the Nutrition They Need)” is a new online seminar based ...
(Date:9/17/2014)... Wailea, Maui, HI (PRWEB) September 17, 2014 ... has announced the eighth annual Wailea Tennis Fantasy ... 19-23, 2014 at Maui’s prestigious Wailea Tennis Club, with ... ranked Lindsay Davenport returning to Wailea, Maui for her ... world-class instruction and match play with Davenport, recently inducted ...
(Date:9/17/2014)... In a new video released for ... expert on the condition known as PPP, demonstrates a proven ... or PPP, is a condition that affects mostly uncircumcised men ... affected as well. The condition is characterized by small bumps ... is not a sexually transmitted disease and generally has no ...
(Date:9/17/2014)... 17, 2014 Request A Test , ... is offering 10% off drug testing through the ... drug tests, including those ordered by employers for workplace or ... of this discount by using promo code DRUG10 when placing ... positives on workplace drug testing, especially for marijuana or THC. ...
Breaking Medicine News(10 mins):Health News:Innovations to Explore Substance Abuse and Mental Health in Upcoming Episode Airing Wednesday, September 24, 2014 via Discovery Channel. 2Health News:Nutritionist Kristen Yarker Offers Parents a Fresh Approach to Prevent Picky Eaters in New Online Seminar 2Health News:Nutritionist Kristen Yarker Offers Parents a Fresh Approach to Prevent Picky Eaters in New Online Seminar 3Health News:Four Seasons Resort Maui at Wailea Announces 8th Annual Wailea Tennis Fantasy Camp 2Health News:Four Seasons Resort Maui at Wailea Announces 8th Annual Wailea Tennis Fantasy Camp 3Health News:New Video Depicts Best Treatment for PPP 2Health News:New Video Depicts Best Treatment for PPP 3Health News:Request A Test Can Save You 10% on Drug Testing 2Health News:Request A Test Can Save You 10% on Drug Testing 3
... Center have found a new method for identifying suspect ... common acute infections in children. ,Traditionally, researchers ... down the virus or bacteria causing it. But that ... not be present in the blood or other easily ...
... from University of Missouri, Columbia indicates that the masculine tendencies ... been assumed all along that such tendencies were the barriers ... this issue. ,Generally it has been said that ... quality is said to aid in their recovery in traumatic ...
... major Ranbaxy Laboratories Ltd says it has obtained tentative approval ... market a drug for insomnia. ,The US unit ... Drugs, US FDA, has determined the Ranbaxy formulations of Zolpidem ... therapeutic effect as that of Ambien tablets of Sanofi Aventis ...
... Health Services called Frontpoint Systems (http://www.frontpointsystems.co.uk /weblog) has ... Royal College of Obstetricians & Gynaecologists indicating a ... ,The site highlights what is wrong ... in the UK has published a letter from ...
... of Virginia Health System suggests that composition of plaque deposits ... a stroke. ,Published in the March edition of ... deposits in the carotid arteries of 102 patients treated at ... likely to have a stroke, physicians may want to take ...
... the risk of death among children aged 12 to 48 ... conducted by researchers at the Johns Hopkins Bloomberg School of ... in mortality among children 1 to11 months of age. The ... The Lancet. ,Zinc is one of the ...
Cached Medicine News:Health News:‘Fingerprints’ to Track Common Infections in Childr 2Health News:‘Fingerprints’ to Track Common Infections in Childr 3Health News:More Evidence of Racial Discrimination in the NHS 2Health News:Calcium in Arterial Plaque is a Good Indicator for Risk of Stroke 2Health News:Zinc Supplements Enhance Immunity in Children 2
(Date:9/17/2014)... 17, 2014 Cardiac Dimensions ® , Inc. ... the TITAN II clinical trial of its enhanced ... improvements in mitral regurgitation, functional improvement, quality of ... and efficacy data, which was consistent with previous ... at the 26 th annual Transcatheter Cardiovascular ...
(Date:9/17/2014)... , Sept. 17, 2014 Isis Pharmaceuticals, ... it has earned a $4 million milestone payment ... associated with the initiation of a Phase 3 ... resistant (MDR), gram-negative bacterial infections.  The Phase 3 ... evaluate the efficacy and safety of plazomicin compared ...
(Date:9/17/2014)... ALTO, Calif. , Sept. 17, 2014  Neuraltus ... the Company,s Phase 2 clinical program of NP001 for ... Lou Gehrig,s disease) are being highlighted today in ... the ALS Research Group , being held in ... to a  post hoc  analysis, administration of a high ...
Breaking Medicine Technology:Cardiac Dimensions Announces New Long-Term Outcomes Data From TITAN II Clinical Trial Demonstrates Safety, Efficacy Of Enhanced CARILLON Mitral Contour System 2Cardiac Dimensions Announces New Long-Term Outcomes Data From TITAN II Clinical Trial Demonstrates Safety, Efficacy Of Enhanced CARILLON Mitral Contour System 3Isis Pharmaceuticals Earns $4 Million from Achaogen for the Initiation of a Phase 3 Study of Plazomicin 2Isis Pharmaceuticals Earns $4 Million from Achaogen for the Initiation of a Phase 3 Study of Plazomicin 3Neuraltus Pharmaceuticals' ALS Treatment Candidate, NP001, Highlighted at ALS Research Group Summit 2Neuraltus Pharmaceuticals' ALS Treatment Candidate, NP001, Highlighted at ALS Research Group Summit 3
Tennant straight tying forceps with extra delicate smooth jaws, 6 mm tying platform, For 9-0 to 11-0 sutures. Overall length 108 mm....
Catalano curved tying forcep has 6 mm V-grove tying platform. Overall length 100 mm....
McPherson curved tying forceps is long has curved shafts with tying platform 4 mm, serrated handle and polished finish. Overall length 110 mm....
McPherson straight tying forceps have straight shafts, tying platforms 4 mm, serrated handle, polished finish, overall length 85 mm....
Medicine Products: